Longer persistence seen with Upadacitinib versus tumor necrosis factor inhibitors in rheumatoid arthritis

3 months ago 12
Patients with rheumatoid arthritis (RA) person longer persistence with upadacitinib than tumor necrosis origin inhibitors (TNFi), according to a survey published online June 23 successful Rheumatology.
Read Entire Article